FDA Warns of Deadly Lung Inflammation from Breast Cancer Drugs

September 19, 2019 — The FDA is warning that certain breast cancer drugs are linked to deadly lung inflammation.

The breast cancer medications are Ibrance® (palbociclib), Kisqali® (ribociclib), and Verzenio® (abemaciclib).

The FDA is concerned about a rare but life-threatening risk of Interstitial Lung Disease (ILD) or pneumonitis, which are side effects that cause serious lung inflammation and potentially death.

Several deaths due to lung inflammation were reported in clinical trials for Ibrance, Kisquali and Verzenio.

Approximately 1-3% of patients on these medications developed lung inflammation during clinical trials. Some of the patients who died had no risk-factors for lung disease.

The FDA is warning patients who take these medications to tell their healthcare professional right away if they develop new or worsening lung problems.

The symptoms may include difficulty breathing, painful or uncomfortable breathing, and shortness of breath while resting or during periods of low activity.

Need a Breast Cancer Drug Injury Lawyer in Texas?

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our law firm for a free case review.